多西他赛与培美曲塞治疗晚期肺腺癌的临床疗效研究

Comparative study on clinical effect between docetaxel and pemetrexed in the treatment of patients with advanced pulmonary adenocarcinoma

目的本研究旨在对比分析多西他赛与培美曲塞治疗晚期肺腺癌的临床疗效,为临床科学用药提供依据。方法将在我院接受治疗的120例病晚期肺腺癌患者随机分为培美曲塞组60例和多西他赛组60例。培美曲塞组进行培美曲塞化疗,疗程为2周;多西他赛组进行多西他赛化疗,疗程为2周。治疗结束后对两种治疗方法的临床疗效进分析对比研究。结果培美曲塞组的临床总有效率明显高于多西他赛组,其临床总有效率可高达41.7%,具有显著性差异P<0.05。结论在治疗晚期肺腺癌的临床疗效上,培美曲塞疗效显著,是一种值得在临床上大力推广的化疗药品。

Objective To comparatively analyze the clinical effect between docetaxel and pemetrexed in the treatment of patients with advanced pulmonary adenocarcinoma. Methods 120 patients with advanced pulmonary were divided into the pemetrexed group （60 cases） and the docetaxel group （60 cases） randomly The total treatment course was two weeks. Their clinical effect was comparatively analyzed between the two groups af- ter the treatment. Results The total clinical effect of pemetrexed group reached 4l. 7%, which was obviously supe- rior to that in the docetaxel group （ P 〈 0. 05）. Conclusion Pemetrexed has a good efficacy in the treatment of pa- tients with advanced pulmonary adenocarcinoma, and it is worth to be promoted widely in clinical practice.